Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2002 22
2003 28
2004 25
2005 34
2006 28
2007 50
2008 60
2009 81
2010 85
2011 105
2012 122
2013 151
2014 142
2015 171
2016 176
2017 186
2018 230
2019 255
2020 365
2021 380
2022 442
2023 402
2024 447
2025 529
2026 160

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,174 results

Results by year

Filters applied: . Clear all
Page 1
A metabolic alarmin from keratinocytes potentiates systemic humoral immunity.
Ji Z, Gao J, Zhang S, Li J, Wu H, Yao J, Ma X, Xin Y, Zhu Y, Zhao M, Zhao Z, Shen K, Wu T, Qian X, Wang J, An H, Li Y, Sun W, Zhao Q, Zhou X, Gao R, Duan Q, Li C, Geng X, Yang M, Xiao R, Liu J, Wang W, Wang J, Fu Y, Zhang JR, Chen X, Tong P, Cheng G, Qi H, Wu L, Zeng W, Xi Q, Zhang L, Lai Y, Yang W, Zhang Y, Lu Q, Liu W. Ji Z, et al. Among authors: yang m. Nature. 2026 Apr;652(8108):209-219. doi: 10.1038/s41586-026-10167-6. Epub 2026 Mar 4. Nature. 2026. PMID: 41781621
Algal optics.
Yang M, Birwa SK, Goldstein RE. Yang M, et al. Phys Rev E. 2026 Feb;113(2-1):024401. doi: 10.1103/fp9l-zykg. Phys Rev E. 2026. PMID: 41857961
Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial.
He Y, Mi N, Cheng Z, Xue H, Han J, Wang H, Wang H, Wu J, Shi X, Zhao S, Duan B, Zhu Y, Zhou Y, Li F, Wang X, Ling H, Wang S, Li Q, Jiang F, Yang M, Bing S, Zheng Q, Ning J, Guo M, Bu Y, Guan L, Li Y, Yang L, Guo W, Pan H, Li X. He Y, et al. Among authors: yang m. Lancet Diabetes Endocrinol. 2025 Oct;13(10):863-873. doi: 10.1016/S2213-8587(25)00196-2. Epub 2025 Aug 22. Lancet Diabetes Endocrinol. 2025. PMID: 40854315 Clinical Trial.
Fbxo42 promotes the degradation of Ataxin-2 granules to trigger terminal Xbp1 signaling.
Santos CC, Schweizer N, Cairrão F, Ramirez J, Osinalde N, Yang M, Gaspar CJ, Rasheva VI, Trigo ML, Hensel Z, Adrain C, Cordeiro TN, Voigt F, Gameiro PA, Mayor U, Domingos PM. Santos CC, et al. Among authors: yang m. Nat Commun. 2025 Aug 13;16(1):7523. doi: 10.1038/s41467-025-62417-2. Nat Commun. 2025. PMID: 40804044 Free PMC article.
The molecular basis of μ-opioid receptor signaling plasticity.
Zhang H, Wang X, Xi K, Shen Q, Xue J, Zhu Y, Zang SK, Yu T, Shen DD, Guo J, Chen LN, Ji SY, Qin J, Dong Y, Zhao M, Yang M, Wu H, Yang G, Zhang Y. Zhang H, et al. Among authors: yang m. Cell Res. 2025 Dec;35(12):1021-1036. doi: 10.1038/s41422-025-01191-8. Epub 2025 Nov 7. Cell Res. 2025. PMID: 41199005 Free PMC article.
Optimal Overlapping Tomography.
Hansenne K, Qu R, Weinbrenner LT, de Gois C, Wang H, Ming Y, Yang Z, Horodecki P, Gao W, Gühne O. Hansenne K, et al. Among authors: ming y. Phys Rev Lett. 2025 Aug 8;135(6):060801. doi: 10.1103/t6qb-kdcp. Phys Rev Lett. 2025. PMID: 40864936
4,174 results